Short Interest in Aytu BioPharma, Inc. (NASDAQ:AYTU) Grows By 8.3%

Aytu BioPharma, Inc. (NASDAQ:AYTU) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 137,300 shares, an increase of 8.3% from the December 31st total of 126,800 shares. Based on an average trading volume of 33,600 shares, the days-to-cover ratio is presently 4.1 days. Currently, 2.3% of the shares of the company are sold short.

Aytu BioPharma Stock Performance

Aytu BioPharma stock traded down $0.03 during mid-day trading on Monday, hitting $1.64. 10,031 shares of the company’s stock traded hands, compared to its average volume of 21,463. Aytu BioPharma has a one year low of $1.30 and a one year high of $3.45. The company has a market cap of $10.09 million, a PE ratio of -1.33 and a beta of -1.45. The firm has a 50 day moving average price of $1.62 and a 200 day moving average price of $2.07. The company has a quick ratio of 0.80, a current ratio of 0.99 and a debt-to-equity ratio of 0.35.

Hedge Funds Weigh In On Aytu BioPharma

A hedge fund recently raised its stake in Aytu BioPharma stock. Stonepine Capital Management LLC increased its stake in Aytu BioPharma, Inc. (NASDAQ:AYTU) by 6.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 500,958 shares of the company’s stock after acquiring an additional 28,489 shares during the period. Aytu BioPharma makes up approximately 0.7% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 25th biggest position. Stonepine Capital Management LLC owned approximately 8.15% of Aytu BioPharma worth $1,177,000 at the end of the most recent reporting period. 33.49% of the stock is owned by hedge funds and other institutional investors.

About Aytu BioPharma

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.